Chimeric Therapeutics news
Further to the announcement of the exclusive option to license the CORE-NK platform released on 21 November 2022, at the request of the ASX, Chimeric Therapeutics (ASX: CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, provides additional information regarding an exclusive license agreement with Case Western Reserve University (CWRU) for the CORE-NK platform, invented by Dr David Wald.
The CORE-NK platform uses a novel, propr
Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that the Japan Patent Office has issued a patent covering certain applications of chimeric antigen receptor (CAR) technology using chlorotoxin (CLTX), including Chimeric’s clinical-stage CAR T asset CHM 1101 and preclinicalstage CAR NK asset CHM 1301.
The patent has been granted under patent number JP 7,085,990, entitled
- Exclusive global license for CORE NK platform (CHM 0201) executed with Case Western Reserve University in Ohio
- Initial Phase 1 clinical trial results of the CORE NK platform (CHM 0201) were published demonstrating safety and encouraging activity in blood cancers and solid tumours
- One patient achieved a complete response that was sustained for over 15 months at time of publication
- Based on the initial CORE NK (CHM 0201) activi
Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has appointed Ms Cassandra Harrison to the position of Vice President (VP) Clinical Operations and Data Management.
Ms Harrison joins Chimeric with more than 10 years experience in clinical operations, compliance, and data management. Until recently, Ms Harrison was Vice President of Clinical Operations and Data Managem
Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has expanded its license agreement with the University of Pennsylvania (Penn) related to CDH17 chimeric antigen receptor (CAR) therapies.
Under the amended agreement, Chimeric has acquired a non-exclusive know-how license to use Penn’s third-generation lentiviral vector plasmid system for the development and co